Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules

Vaccine

Volumn 19, Issue 25-26, 2001, Pages 3552-3567

  Hodge, James W ^a   Grosenbach, Douglas W ^a   Rad, Ariel N ^b   Giuliano, Mariateresa ^a   Sabzevari, Helen ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Costimulation; Fowlpox; Splenocytes; T cells; Vaccine; Vaccinia

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENCY; EXPRESSION VECTOR; FEMALE; FOWLPOX VIRUS; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRICOM VECTOR; VACCINIA VIRUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD58; ANTIGENS, CD80; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; FOWLPOX VIRUS; GENETIC VECTORS; IMMUNOLOGIC MEMORY; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-2; ISCOMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OVALBUMIN; SPLEEN; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 0035858131     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00062-7     Document Type: Article

References (42)

1. + T lymphocytes
2. Costimulation of T-cell-mediated tumor immunity
3. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
4. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles
5. + T cells
6. + T cell activation but both are required for optimum response
7. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response
8. Immunotherapy of cancer with dendritic-cell-based vaccines
9. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
10. Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: Antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1
11. Dendritic cells require maturation via CD40 to generate protective antitumor immunity
12. Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches
13. A triad of costimulatory molecules synergize to amplify T cell activation
14. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
15. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
16. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus
17. Compact, synthetic, vaccinia virus early/late promoter for protein expression
18. Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment
19. Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene
20. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity
21. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21
22. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
23. Exact prediction of a natural T cell epitope
24. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes
25. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
26. Comparative analysis of murine dendritic cells derived from spleen and bone marrow
27. A less costly method for obtaining dendritic cells from peripheral blood adherent mononuclear cells using low doses of GM-CSF +IL-4+IFN-γ
28. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
29. Proliferating dendritic cell progenitors in human blood
30. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells
31. Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1
32. Expression of B7 costimulator molecules on mouse dendritic cells
33. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes
34. CD28 and apoptosis
35. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL
36. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: Second interim analysis of data from a phase III, multi-institutional trial
37. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial
38. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
39. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells
40. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
41. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses